Skip to content
Sign in

SNOA · NASDAQ

Sonoma Pharmaceuticals (SNOA) Stock Price & Fundamentals

$743.29−0.48%−$3.55End-of-day price as of Oct 9, 2026

Sonoma Pharmaceuticals (SNOA) closed at $743.29 on Oct 9, 2026, down 0.48% from the previous close of $746.84.

Share price, past year

1Y +16.86%

52-week range $607.15 – $748.39. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$743.29
Sep 30, 2026$729.32
Aug 31, 2026$710.78
Jul 31, 2026$701.66
Jun 30, 2026$743.89
May 29, 2026$710.61
Apr 30, 2026$739.43
Mar 31, 2026$713.32
Feb 27, 2026$682.26
Jan 30, 2026$684.25
Dec 31, 2025$700.04
Nov 28, 2025$704.91
Oct 31, 2025$617.34

Key statistics

Market cap
$3.56B
P/E (TTM)
—
EPS (TTM)
−$1.22
Revenue (TTM)
$21.92M
Net income (TTM)
−$2.26M
Shares outstanding
4.8M
Dividend yield
—
52-week range
$607.15 – $748.39

Sonoma Pharmaceuticals's market cap is $3.56B, based on a share price of $743.29 and 4.8M shares outstanding as of Jun 30, 2026.

Financials

Sonoma Pharmaceuticals reported revenue of $19.53M for fiscal 2026, up 36.68% from fiscal 2025.

Sonoma Pharmaceuticals reported a net loss of $3.18M in fiscal 2026.

Fiscal 2026 revenue was the highest in the 10 years shown.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Annual revenue by fiscal year; the table below lists the values.
Sonoma Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2026ended Mar 31, 2026$19.53M+36.7%−$3.18M−16.3%−$1.89−$4.13M
FY2025ended Mar 31, 2025$14.29M+12.2%−$3.46M−24.2%−$2.79−$168.00K
FY2024ended Mar 31, 2024$12.74M−4.1%−$4.84M−38.0%−$10.63−$2.40M
FY2023ended Mar 31, 2023$13.27M+5.1%−$5.15M−38.8%−$1.52−$6.42M
FY2022ended Mar 31, 2022$12.63M−32.2%−$5.09M−40.3%−$1.92−$4.39M
FY2021ended Mar 31, 2021$18.63M+3.9%−$3.95M−21.2%−$1.97−$3.56M
FY2020ended Mar 31, 2020$17.93M−5.5%−$3.31M−18.5%−$2.24−$4.80M
FY2019ended Mar 31, 2019$18.97M+13.9%−$11.80M−62.2%−$12.77−$11.82M
FY2018ended Mar 31, 2018$16.66M+29.9%−$14.33M−86.0%−$256.41—
FY2017ended Mar 31, 2017$12.83M—$9.27M72.3%$19.80—
Sonoma Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q1 FY2027ended Jun 30, 2026$6.41M−$330.00K−$0.09
Q4 FY2026ended Mar 31, 2026$5.56M−$581.00K−$0.33
Q3 FY2026ended Dec 31, 2025$4.35M−$819.00K−$0.48
Q2 FY2026ended Sep 30, 2025$5.60M−$534.00K−$0.32
Q1 FY2026ended Jun 30, 2025$4.02M−$1.24M−$0.76
Q4 FY2025ended Mar 31, 2025$3.75M−$776.00K−$0.23
Q3 FY2025ended Dec 31, 2024$3.56M−$928.00K−$0.63
Q2 FY2025ended Sep 30, 2024$3.58M−$610.00K−$0.59

Company profile

Name
Sonoma Pharmaceuticals, Inc.
Ticker
SNOA
Exchange
NASDAQ
Industry (SEC SIC)
Surgical & Medical Instruments & Apparatus
Headquarters
5445 Conestoga Court, Suite 150, Boulder, CO 80301
Incorporated in
DE
Fiscal year ends
March
SEC CIK
0001367083

Recent SEC filings

Frequently asked questions

What is Sonoma Pharmaceuticals's stock price?

Sonoma Pharmaceuticals (SNOA) closed at $743.29 on Oct 9, 2026, down 0.48% from the previous close of $746.84.

What is Sonoma Pharmaceuticals's market cap?

Sonoma Pharmaceuticals's market cap is $3.56B, based on a share price of $743.29 and 4.8M shares outstanding as of Jun 30, 2026.

How much revenue does Sonoma Pharmaceuticals make?

Sonoma Pharmaceuticals reported revenue of $19.53M for fiscal 2026, up 36.68% from fiscal 2025.

Does Sonoma Pharmaceuticals pay a dividend?

Sonoma Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Sonoma Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures